Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 565 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... October 12, 2021 A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... January 12, 2026 Medicare Open Enrollment is Here! October 17, 2022 New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 Load more HOT NEWS Tailored Psychotherapy Eases Depression in People with Advanced Cancer EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and...
